BDA-366 NEW
| Price | $47 | $110 | $187 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-26 |
Product Details
| Product Name: BDA-366 | CAS No.: 1909226-00-1 |
| Purity: 99.46% | Supply Ability: 10g |
| Release date: 2025/05/26 |
Product Introduction
Bioactivity
| Name | BDA-366 |
| Description | BDA-366, a potent Bcl2 antagonist, selectively binds the Bcl2-BH4 domain with high affinity (Ki = 3.3 nM), inducing a conformational change that nullifies its antiapoptotic function, thereby transforming it into a pro-apoptotic entity. This compound effectively suppresses lung cancer cell growth[1]. |
| In vitro | NSC 228155 promotes transactivation of several RTKs, including ErbB2 and ErbB3, Insulin R and IGF-1 R receptors in the cells. It stimulates dimerization of sEGFR domain II[1]. NSC 228155 can rapidly move across cell membranes and disperse within both cytoplasmic and nuclear compartments. It rapidly generates hydrogen peroxide within cells[2]. NSC 228155 is also a potent inhibitor of KIX-KID interaction(IC50 = 0.36 μM), but it is not particularly selective against CREB-mediated gene transcription in HEK 293T cells[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 5 mg/mL (11.81 mM), Sonication is recommended. DMSO : 78 mg/mL (184.18 mM), Sonication is recommended. |
| Keywords | Lung cancer | Inhibitor | inhibit | BDA-366 | BDA366 | BDA 366 | Bcl2-BH4 domain | Bcl-2 Family | Antitumor | Anticancer | Antiapoptotic function |
| Inhibitors Related | Gossypol (acetic acid) | (S)-(+)-Ibuprofen | Allethrin | Erianin | Navitoclax | Gossypol | Triacetylresveratrol | Diphenyl disulfide | Lisaftoclax | Venetoclax | Sonrotoclax TFA | Thymoquinone |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Lung Cancer Compound Library | Cuproptosis Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-30 | |
| $0.00/20Kg/Drum |
VIP5Y
|
CHINATECH(TIANJIN) CHEMICAL CO.,LTD.
|
2021-12-15 | |
| $10.00/1KG |
Shijiazhuang tongyang Import and Export Co., LTD
|
2021-08-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY